Review



macs kit  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 97
      Buy from Supplier

    Structured Review

    Miltenyi Biotec macs kit
    Macs Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 634 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd8a/CD8a%2B+T+Cell+Isolation+Kit%2C+mouse/pmc13623212-796-12-14
    Average 97 stars, based on 634 article reviews
    macs kit - by Bioz Stars, 2026-10
    97/100 stars

    Images

    Related Articles

    Isolation:

    Article Title: Combined innate immune cell therapy, tumor-specific antibody, and radiation prompt antitumor response in pancreatic cancer models.
    Article Snippet: Blood within groups of mice was pooled to isolate PBMCs through Ficoll gradient centrifugation (Thermo Fisher Scientific). .. CD8+ T cells were isolated from PBMCs using CD8a (Ly- 2) MicroBeads (Miltenyi Biotec). .. IFN- γ and TNFα concentrations in supernatants were determined using a multiplex immunoassay (MILLIPLEX MAP human Cytokine/Chemokine Magnetic Bead Panel, MilliporeSigma) following the manufacturer’s instructions with quantification on the Luminex xMAP INTELLIFLEX systems (Thermo Fisher Scientific).

    Article Title: Macrophage WDFY3 mitigates autoimmunity by enhancing efferocytosis and suppressing T cell activation in mice
    Article Snippet: .. CD4 + T cells or CD8 + T cells were isolated from spleen single-cell suspensions of OT-II mice or OT-I mice, respectively, using CD4 (Miltenyi Biotec, 130-117-043) or CD8a (Miltenyi Biotec, 130-117-044) MicroBeads. .. Isolated T cells were labeled with 5 μM carboxyfluorescein succinimidyl ester (CFSE)-Violet Proliferation Dye 450 (VPD450, BD Horizon, 562158) for 25 min. For MHC-II-mediated antigen presentation, BMDMs were pulsed with OVA 323-339 peptide (20 μg/mL, Anaspec, 50-843-886) for 24 h, followed by co-culture with CD4 + OT-II T cells for 72 h. For MHC-I-mediated antigen presentation, BMDMs were pulsed with OVA 257-264 peptide (20 μg/mL, Anaspec, 50-844-730) for 24 h, followed by co-culture with CD8 + OT-I T cells for 72 h. T cell proliferation was assessed by measuring CFSE-VPD450 dilution in CD4 + T cells (CD4-APC, Invitrogen, 17-0041-81, 1:100) or CD8 + T cells (CD8a-FITC, Invitrogen, 11-0081-82, 1:100) using a NovoCyte flow cytometer, as each round of division corresponds to a reduction in CFSE-VPD450 fluorescence intensity, thereby serving as a marker for T cell proliferation.

    Lysis:

    Article Title: Dual regulation of CXCR6 + CD8 + T cells modulates cytotoxic and exhaustion-associated programs during prostate cancer progression.
    Article Snippet: .. Following lysis, the cell pellet was collected for enrichment of murine splenic CD8+ T cells using CD8a (Ly- 2) MicroBeads (mouse, Miltenyi Biotec, 130- 117- 044) according to the manufacturer’s instructions. .. Briefly, cells were resuspended in autoMACS Running Buffer (90 μL per 107 cells), incubated with 10 μL MicroBeads at 4°C for 30 min, and subsequently separated using an LS Column.

    Staining:

    Article Title: Sez6L2 autoimmunity induces cerebellar ataxia in mice.
    Article Snippet: Plates 232 were washed once in FACS buffer (PBS with 0.5% BSA) and then incubated for 10 233 minutes with an Fc block (1:25 dilution, BioLegend, Fc Block - Mouse TruStain FcXTM 234 PLUS, 156604). .. Cell surface antigens were then stained for 30 minutes using 235 antibodies to CD3 (Super Bright Violet 570, Bio-Rad, MCA500SBV570), CD4 236 (AlexaFluor488, BioLegend, 100532), CD8a (PE-Vio770, Miltenyi Biotechnology, 130- 237 120-817), CD14 (Super Bright 436, Thermo Fisher, 62-0141-80) and/or CD19 (Violet 238 Fluor 450, Tonbo Biosciences, 75-0193-U025). .. Cells were then washed three times 239 with FACS buffer and incubated in FluoroFixTM buffer (BioLegend, 422101) for 60 240 minutes.

    Article Title: Serial multichannel microscopy
    Article Snippet: .. The staining were done using the following 11 antibodies, Ki67 available from Miltenyi Biotec B.V. & Co. KG as REA 183 antibody (A1,A2, cycle 1), KLRG1 available from Miltenyi Biotec B.V. & Co. KG as REA 1016 antibody, (B1,B2, cycle 2), NK1.1 available from Miltenyi Biotec B.V. & Co. KG as REA 1162 antibody, (C1,C2, cycle 3), CD8a available from Miltenyi Biotec B.V. & Co. KG as REA601 antibody (D1, D2, cycle 4), CD1 lb available from Miltenyi Biotec B.V. & Co. KG as REA593, (A3, A4, cycle 5), F4/80 available from Miltenyi Biotec B.V. & Co. KG as REA126, (B3,B4, cycle 6), CD184 available from Miltenyi Biotec B.V. & Co. KG as REA107, (C3,C4, cycle 7), GR-1 antibody as monoclonal antibody with the clone name RB6-8C5 available from Miltenyi Biotec B.V. & Co. KG, (D3, D4, cycle 8), CD15 anti mouse Clone MC-480 antibody from Biolegend, (A5, A6, cycle 9), LY-49A available from Miltenyi Biotec B.V. & Co. KG as REAL436, (B5, B6, cycle 10) and IgM available from Miltenyi Biotec B.V. & Co. KG as REA979 (C5, C6, cycle 11). ..

    Article Title: Sez6L2 autoimmunity induces cerebellar ataxia in mice
    Article Snippet: Cells were pelleted (spin 400xg for 5 min) and stained with Ghost Dye Violet 450 (Tonbo Biosciences, 13–0863-T100) in PBS for 10 to 15 min. Plates were washed once in FACS buffer (PBS with 0.5% BSA) and then incubated for 10 min with an Fc block (1:25 dilution, BioLegend, Fc Block - Mouse TruStain FcXTM PLUS, 156604). .. Cell surface antigens were then stained for 30 min using antibodies to CD3 (Super Bright Violet 570, Bio-Rad, MCA500SBV570), CD4 (AlexaFluor488, BioLegend, 100532), CD8a (PE-Vio770, Miltenyi Biotechnology, 130-120−817), CD14 (Super Bright 436, Thermo Fisher, 62–0141−80) and/or CD19 (Violet Fluor 450, Tonbo Biosciences, 75–0193-U025). .. Cells were then washed three times with FACS buffer and incubated in FluoroFix TM buffer (BioLegend, 422101) for 60 min.

    Cell Isolation:

    Article Title: Tumor-derived RAC1 A159V mutation promotes an immunosuppressive microenvironment that represses response to immune checkpoint inhibitor.
    Article Snippet: .. The CD8+ T cell isolation was performed using CD8a (Ly- 2) MicroBeads (Miltenyi Biotec, catalog no. 130- 117- 044) according to the manufacturer’s protocol. ..

    Single Cell:

    Article Title: Macrophage WDFY3 mitigates autoimmunity by enhancing efferocytosis and suppressing T cell activation in mice
    Article Snippet: .. CD4 + T cells or CD8 + T cells were isolated from spleen single-cell suspensions of OT-II mice or OT-I mice, respectively, using CD4 (Miltenyi Biotec, 130-117-043) or CD8a (Miltenyi Biotec, 130-117-044) MicroBeads. .. Isolated T cells were labeled with 5 μM carboxyfluorescein succinimidyl ester (CFSE)-Violet Proliferation Dye 450 (VPD450, BD Horizon, 562158) for 25 min. For MHC-II-mediated antigen presentation, BMDMs were pulsed with OVA 323-339 peptide (20 μg/mL, Anaspec, 50-843-886) for 24 h, followed by co-culture with CD4 + OT-II T cells for 72 h. For MHC-I-mediated antigen presentation, BMDMs were pulsed with OVA 257-264 peptide (20 μg/mL, Anaspec, 50-844-730) for 24 h, followed by co-culture with CD8 + OT-I T cells for 72 h. T cell proliferation was assessed by measuring CFSE-VPD450 dilution in CD4 + T cells (CD4-APC, Invitrogen, 17-0041-81, 1:100) or CD8 + T cells (CD8a-FITC, Invitrogen, 11-0081-82, 1:100) using a NovoCyte flow cytometer, as each round of division corresponds to a reduction in CFSE-VPD450 fluorescence intensity, thereby serving as a marker for T cell proliferation.



    Similar Products

    cd8a antibody  (NSJ Bioreagents)
    94
    NSJ Bioreagents cd8a antibody
    Cd8a Antibody, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd8a/CD8a+Antibody/custom%40v8216%4010%2E3390%2Fijms27188338
    Average 94 stars, based on 1 article reviews
    cd8a antibody - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    macs kit  (Miltenyi Biotec)
    97
    Miltenyi Biotec macs kit
    Macs Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd8a/CD8a%2B+T+Cell+Isolation+Kit%2C+mouse/pmc13623212-796-12-14
    Average 97 stars, based on 1 article reviews
    macs kit - by Bioz Stars, 2026-10
    97/100 stars
    		  Buy from Supplier
    anti mouse cd8a  (Bio X Cell)
    97
    Bio X Cell anti mouse cd8a
    Proangiogenic and immunosuppression phenotype of TANs in the CRLM microenvironment. A, Heatmap showing signature scores for angiogenesis, myeloid cell recruitment, neutrophil cytotoxicity, MDSC, and NET across each TAN and PMN subset. B, Comparison of angiogenesis, myeloid cell recruitment, MDSC, and NET signature scores among TAN and PMN subsets. C, Dot plot illustrating expression levels of major cytokines and chemokines in each TAN and PMN subset. D, Representative IHC images of CD31 staining in CRLM tissues. Scale bars, 50 µm. E, Correlation analysis between CD31 and TAN1 density using Spearman’s rank correlation ( n = 102). F, Representative images and quantification of tube formation in HUVECs when cocultured with conditioned medium from human LGALS3 − neutrophils or LGALS3 + neutrophils ( n = 6). G, UMAP plot showing six monocyte/macrophage subsets across colorectal cancer, adjacent liver tissues, CRLM, and PB samples. H, Shell-like plot depicting ligand–receptor interaction strength between TAN1_LGASL3 and neutrophil/monocyte/macrophage subset in CRLM. I, Selected ligand–receptor interactions between TAN1_LGASL3 and neutrophil/monocyte/macrophage subset in CRLM. J, Representative mIHC images of CD68, CCL3L1, CD66b, CCR1, and BHLHE40 in CRLM. Scale bars, 50 µm. K, Representative images of macrophage migration assays and effects of conditioned medium from human LGALS3 + neutrophils on migration of macrophages (induced from THP-1 cells) in the presence of CCR1 inhibitor (BX471) or anti-CCL3 antibody ( n = 6). L, Comparison of immunosuppressive macrophage signature scores between colorectal cancer and CRLM. M, Schematic of the CRLM mouse model. C57BL/6 mice received intrasplenic injections of mouse colorectal cancer cells (MC38). Mice were subsequently treated with IgG control (IgG; n = 6), anti-Ly6G antibody (anti-Ly6G; n = 6), or anti-Ly6G plus <t>anti-CD8a</t> antibodies (anti-Ly6G + anti-CD8a; n = 6). Livers were harvested on day 14. N, Representative images of liver metastases from IgG, anti-Ly6G, and anti-Ly6G + anti-CD8a groups. O, Comparison of liver weights among the three groups. P values were calculated by the Wilcoxon rank-sum test ( B and L ) and unpaired Student t test ( F , K , and O ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. CRC, colorectal cancer; Ctrl, control.
    Anti Mouse Cd8a, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd8a/InVivoMAb+anti-mouse+CD8%CE%B1/pmc13628106-246-7-9
    Average 97 stars, based on 1 article reviews
    anti mouse cd8a - by Bioz Stars, 2026-10
    97/100 stars
    		  Buy from Supplier
    gb21303 apc anti mouse cd8a antibody proteintech  (Proteintech)
    93
    Proteintech gb21303 apc anti mouse cd8a antibody proteintech
    Proangiogenic and immunosuppression phenotype of TANs in the CRLM microenvironment. A, Heatmap showing signature scores for angiogenesis, myeloid cell recruitment, neutrophil cytotoxicity, MDSC, and NET across each TAN and PMN subset. B, Comparison of angiogenesis, myeloid cell recruitment, MDSC, and NET signature scores among TAN and PMN subsets. C, Dot plot illustrating expression levels of major cytokines and chemokines in each TAN and PMN subset. D, Representative IHC images of CD31 staining in CRLM tissues. Scale bars, 50 µm. E, Correlation analysis between CD31 and TAN1 density using Spearman’s rank correlation ( n = 102). F, Representative images and quantification of tube formation in HUVECs when cocultured with conditioned medium from human LGALS3 − neutrophils or LGALS3 + neutrophils ( n = 6). G, UMAP plot showing six monocyte/macrophage subsets across colorectal cancer, adjacent liver tissues, CRLM, and PB samples. H, Shell-like plot depicting ligand–receptor interaction strength between TAN1_LGASL3 and neutrophil/monocyte/macrophage subset in CRLM. I, Selected ligand–receptor interactions between TAN1_LGASL3 and neutrophil/monocyte/macrophage subset in CRLM. J, Representative mIHC images of CD68, CCL3L1, CD66b, CCR1, and BHLHE40 in CRLM. Scale bars, 50 µm. K, Representative images of macrophage migration assays and effects of conditioned medium from human LGALS3 + neutrophils on migration of macrophages (induced from THP-1 cells) in the presence of CCR1 inhibitor (BX471) or anti-CCL3 antibody ( n = 6). L, Comparison of immunosuppressive macrophage signature scores between colorectal cancer and CRLM. M, Schematic of the CRLM mouse model. C57BL/6 mice received intrasplenic injections of mouse colorectal cancer cells (MC38). Mice were subsequently treated with IgG control (IgG; n = 6), anti-Ly6G antibody (anti-Ly6G; n = 6), or anti-Ly6G plus <t>anti-CD8a</t> antibodies (anti-Ly6G + anti-CD8a; n = 6). Livers were harvested on day 14. N, Representative images of liver metastases from IgG, anti-Ly6G, and anti-Ly6G + anti-CD8a groups. O, Comparison of liver weights among the three groups. P values were calculated by the Wilcoxon rank-sum test ( B and L ) and unpaired Student t test ( F , K , and O ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. CRC, colorectal cancer; Ctrl, control.
    Gb21303 Apc Anti Mouse Cd8a Antibody Proteintech, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd8a/APC+Anti-mouse+CD8a/pm42810343-283-261-266
    Average 93 stars, based on 1 article reviews
    gb21303 apc anti mouse cd8a antibody proteintech - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    anti cd8a  (Bio X Cell)
    95
    Bio X Cell anti cd8a
    Proangiogenic and immunosuppression phenotype of TANs in the CRLM microenvironment. A, Heatmap showing signature scores for angiogenesis, myeloid cell recruitment, neutrophil cytotoxicity, MDSC, and NET across each TAN and PMN subset. B, Comparison of angiogenesis, myeloid cell recruitment, MDSC, and NET signature scores among TAN and PMN subsets. C, Dot plot illustrating expression levels of major cytokines and chemokines in each TAN and PMN subset. D, Representative IHC images of CD31 staining in CRLM tissues. Scale bars, 50 µm. E, Correlation analysis between CD31 and TAN1 density using Spearman’s rank correlation ( n = 102). F, Representative images and quantification of tube formation in HUVECs when cocultured with conditioned medium from human LGALS3 − neutrophils or LGALS3 + neutrophils ( n = 6). G, UMAP plot showing six monocyte/macrophage subsets across colorectal cancer, adjacent liver tissues, CRLM, and PB samples. H, Shell-like plot depicting ligand–receptor interaction strength between TAN1_LGASL3 and neutrophil/monocyte/macrophage subset in CRLM. I, Selected ligand–receptor interactions between TAN1_LGASL3 and neutrophil/monocyte/macrophage subset in CRLM. J, Representative mIHC images of CD68, CCL3L1, CD66b, CCR1, and BHLHE40 in CRLM. Scale bars, 50 µm. K, Representative images of macrophage migration assays and effects of conditioned medium from human LGALS3 + neutrophils on migration of macrophages (induced from THP-1 cells) in the presence of CCR1 inhibitor (BX471) or anti-CCL3 antibody ( n = 6). L, Comparison of immunosuppressive macrophage signature scores between colorectal cancer and CRLM. M, Schematic of the CRLM mouse model. C57BL/6 mice received intrasplenic injections of mouse colorectal cancer cells (MC38). Mice were subsequently treated with IgG control (IgG; n = 6), anti-Ly6G antibody (anti-Ly6G; n = 6), or anti-Ly6G plus <t>anti-CD8a</t> antibodies (anti-Ly6G + anti-CD8a; n = 6). Livers were harvested on day 14. N, Representative images of liver metastases from IgG, anti-Ly6G, and anti-Ly6G + anti-CD8a groups. O, Comparison of liver weights among the three groups. P values were calculated by the Wilcoxon rank-sum test ( B and L ) and unpaired Student t test ( F , K , and O ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. CRC, colorectal cancer; Ctrl, control.
    Anti Cd8a, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd8a/InVivoMAb+anti-mouse+CD8%CE%B1/pm42782159-280-25-29
    Average 95 stars, based on 1 article reviews
    anti cd8a - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    pe anti mouse cd8  (Proteintech)
    93
    Proteintech pe anti mouse cd8
    Proangiogenic and immunosuppression phenotype of TANs in the CRLM microenvironment. A, Heatmap showing signature scores for angiogenesis, myeloid cell recruitment, neutrophil cytotoxicity, MDSC, and NET across each TAN and PMN subset. B, Comparison of angiogenesis, myeloid cell recruitment, MDSC, and NET signature scores among TAN and PMN subsets. C, Dot plot illustrating expression levels of major cytokines and chemokines in each TAN and PMN subset. D, Representative IHC images of CD31 staining in CRLM tissues. Scale bars, 50 µm. E, Correlation analysis between CD31 and TAN1 density using Spearman’s rank correlation ( n = 102). F, Representative images and quantification of tube formation in HUVECs when cocultured with conditioned medium from human LGALS3 − neutrophils or LGALS3 + neutrophils ( n = 6). G, UMAP plot showing six monocyte/macrophage subsets across colorectal cancer, adjacent liver tissues, CRLM, and PB samples. H, Shell-like plot depicting ligand–receptor interaction strength between TAN1_LGASL3 and neutrophil/monocyte/macrophage subset in CRLM. I, Selected ligand–receptor interactions between TAN1_LGASL3 and neutrophil/monocyte/macrophage subset in CRLM. J, Representative mIHC images of CD68, CCL3L1, CD66b, CCR1, and BHLHE40 in CRLM. Scale bars, 50 µm. K, Representative images of macrophage migration assays and effects of conditioned medium from human LGALS3 + neutrophils on migration of macrophages (induced from THP-1 cells) in the presence of CCR1 inhibitor (BX471) or anti-CCL3 antibody ( n = 6). L, Comparison of immunosuppressive macrophage signature scores between colorectal cancer and CRLM. M, Schematic of the CRLM mouse model. C57BL/6 mice received intrasplenic injections of mouse colorectal cancer cells (MC38). Mice were subsequently treated with IgG control (IgG; n = 6), anti-Ly6G antibody (anti-Ly6G; n = 6), or anti-Ly6G plus <t>anti-CD8a</t> antibodies (anti-Ly6G + anti-CD8a; n = 6). Livers were harvested on day 14. N, Representative images of liver metastases from IgG, anti-Ly6G, and anti-Ly6G + anti-CD8a groups. O, Comparison of liver weights among the three groups. P values were calculated by the Wilcoxon rank-sum test ( B and L ) and unpaired Student t test ( F , K , and O ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. CRC, colorectal cancer; Ctrl, control.
    Pe Anti Mouse Cd8, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd8a/PE+Anti-mouse+CD8a/pm42785880-55-14-21
    Average 93 stars, based on 1 article reviews
    pe anti mouse cd8 - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    fluorescein isothiocyanate anti human cd8a  (ABclonal Biotechnology)
    95
    ABclonal Biotechnology fluorescein isothiocyanate anti human cd8a
    Proangiogenic and immunosuppression phenotype of TANs in the CRLM microenvironment. A, Heatmap showing signature scores for angiogenesis, myeloid cell recruitment, neutrophil cytotoxicity, MDSC, and NET across each TAN and PMN subset. B, Comparison of angiogenesis, myeloid cell recruitment, MDSC, and NET signature scores among TAN and PMN subsets. C, Dot plot illustrating expression levels of major cytokines and chemokines in each TAN and PMN subset. D, Representative IHC images of CD31 staining in CRLM tissues. Scale bars, 50 µm. E, Correlation analysis between CD31 and TAN1 density using Spearman’s rank correlation ( n = 102). F, Representative images and quantification of tube formation in HUVECs when cocultured with conditioned medium from human LGALS3 − neutrophils or LGALS3 + neutrophils ( n = 6). G, UMAP plot showing six monocyte/macrophage subsets across colorectal cancer, adjacent liver tissues, CRLM, and PB samples. H, Shell-like plot depicting ligand–receptor interaction strength between TAN1_LGASL3 and neutrophil/monocyte/macrophage subset in CRLM. I, Selected ligand–receptor interactions between TAN1_LGASL3 and neutrophil/monocyte/macrophage subset in CRLM. J, Representative mIHC images of CD68, CCL3L1, CD66b, CCR1, and BHLHE40 in CRLM. Scale bars, 50 µm. K, Representative images of macrophage migration assays and effects of conditioned medium from human LGALS3 + neutrophils on migration of macrophages (induced from THP-1 cells) in the presence of CCR1 inhibitor (BX471) or anti-CCL3 antibody ( n = 6). L, Comparison of immunosuppressive macrophage signature scores between colorectal cancer and CRLM. M, Schematic of the CRLM mouse model. C57BL/6 mice received intrasplenic injections of mouse colorectal cancer cells (MC38). Mice were subsequently treated with IgG control (IgG; n = 6), anti-Ly6G antibody (anti-Ly6G; n = 6), or anti-Ly6G plus <t>anti-CD8a</t> antibodies (anti-Ly6G + anti-CD8a; n = 6). Livers were harvested on day 14. N, Representative images of liver metastases from IgG, anti-Ly6G, and anti-Ly6G + anti-CD8a groups. O, Comparison of liver weights among the three groups. P values were calculated by the Wilcoxon rank-sum test ( B and L ) and unpaired Student t test ( F , K , and O ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. CRC, colorectal cancer; Ctrl, control.
    Fluorescein Isothiocyanate Anti Human Cd8a, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd8a/CD8A+Rabbit+pAb/pmc13557068-235-21-25
    Average 95 stars, based on 1 article reviews
    fluorescein isothiocyanate anti human cd8a - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    naive cd8a t cell isolation kit  (Miltenyi Biotec)
    96
    Miltenyi Biotec naive cd8a t cell isolation kit
    Proangiogenic and immunosuppression phenotype of TANs in the CRLM microenvironment. A, Heatmap showing signature scores for angiogenesis, myeloid cell recruitment, neutrophil cytotoxicity, MDSC, and NET across each TAN and PMN subset. B, Comparison of angiogenesis, myeloid cell recruitment, MDSC, and NET signature scores among TAN and PMN subsets. C, Dot plot illustrating expression levels of major cytokines and chemokines in each TAN and PMN subset. D, Representative IHC images of CD31 staining in CRLM tissues. Scale bars, 50 µm. E, Correlation analysis between CD31 and TAN1 density using Spearman’s rank correlation ( n = 102). F, Representative images and quantification of tube formation in HUVECs when cocultured with conditioned medium from human LGALS3 − neutrophils or LGALS3 + neutrophils ( n = 6). G, UMAP plot showing six monocyte/macrophage subsets across colorectal cancer, adjacent liver tissues, CRLM, and PB samples. H, Shell-like plot depicting ligand–receptor interaction strength between TAN1_LGASL3 and neutrophil/monocyte/macrophage subset in CRLM. I, Selected ligand–receptor interactions between TAN1_LGASL3 and neutrophil/monocyte/macrophage subset in CRLM. J, Representative mIHC images of CD68, CCL3L1, CD66b, CCR1, and BHLHE40 in CRLM. Scale bars, 50 µm. K, Representative images of macrophage migration assays and effects of conditioned medium from human LGALS3 + neutrophils on migration of macrophages (induced from THP-1 cells) in the presence of CCR1 inhibitor (BX471) or anti-CCL3 antibody ( n = 6). L, Comparison of immunosuppressive macrophage signature scores between colorectal cancer and CRLM. M, Schematic of the CRLM mouse model. C57BL/6 mice received intrasplenic injections of mouse colorectal cancer cells (MC38). Mice were subsequently treated with IgG control (IgG; n = 6), anti-Ly6G antibody (anti-Ly6G; n = 6), or anti-Ly6G plus <t>anti-CD8a</t> antibodies (anti-Ly6G + anti-CD8a; n = 6). Livers were harvested on day 14. N, Representative images of liver metastases from IgG, anti-Ly6G, and anti-Ly6G + anti-CD8a groups. O, Comparison of liver weights among the three groups. P values were calculated by the Wilcoxon rank-sum test ( B and L ) and unpaired Student t test ( F , K , and O ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. CRC, colorectal cancer; Ctrl, control.
    Naive Cd8a T Cell Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd8a/Naive+CD8a%2B+T+Cell+Isolation+Kit%2C+mouse/pmc13623212-1276-0-8
    Average 96 stars, based on 1 article reviews
    naive cd8a t cell isolation kit - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    cd8a antibody, anti-human, reafinity  (Miltenyi Biotec)
    94
    Miltenyi Biotec cd8a antibody, anti-human, reafinity
    Proangiogenic and immunosuppression phenotype of TANs in the CRLM microenvironment. A, Heatmap showing signature scores for angiogenesis, myeloid cell recruitment, neutrophil cytotoxicity, MDSC, and NET across each TAN and PMN subset. B, Comparison of angiogenesis, myeloid cell recruitment, MDSC, and NET signature scores among TAN and PMN subsets. C, Dot plot illustrating expression levels of major cytokines and chemokines in each TAN and PMN subset. D, Representative IHC images of CD31 staining in CRLM tissues. Scale bars, 50 µm. E, Correlation analysis between CD31 and TAN1 density using Spearman’s rank correlation ( n = 102). F, Representative images and quantification of tube formation in HUVECs when cocultured with conditioned medium from human LGALS3 − neutrophils or LGALS3 + neutrophils ( n = 6). G, UMAP plot showing six monocyte/macrophage subsets across colorectal cancer, adjacent liver tissues, CRLM, and PB samples. H, Shell-like plot depicting ligand–receptor interaction strength between TAN1_LGASL3 and neutrophil/monocyte/macrophage subset in CRLM. I, Selected ligand–receptor interactions between TAN1_LGASL3 and neutrophil/monocyte/macrophage subset in CRLM. J, Representative mIHC images of CD68, CCL3L1, CD66b, CCR1, and BHLHE40 in CRLM. Scale bars, 50 µm. K, Representative images of macrophage migration assays and effects of conditioned medium from human LGALS3 + neutrophils on migration of macrophages (induced from THP-1 cells) in the presence of CCR1 inhibitor (BX471) or anti-CCL3 antibody ( n = 6). L, Comparison of immunosuppressive macrophage signature scores between colorectal cancer and CRLM. M, Schematic of the CRLM mouse model. C57BL/6 mice received intrasplenic injections of mouse colorectal cancer cells (MC38). Mice were subsequently treated with IgG control (IgG; n = 6), anti-Ly6G antibody (anti-Ly6G; n = 6), or anti-Ly6G plus <t>anti-CD8a</t> antibodies (anti-Ly6G + anti-CD8a; n = 6). Livers were harvested on day 14. N, Representative images of liver metastases from IgG, anti-Ly6G, and anti-Ly6G + anti-CD8a groups. O, Comparison of liver weights among the three groups. P values were calculated by the Wilcoxon rank-sum test ( B and L ) and unpaired Student t test ( F , K , and O ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. CRC, colorectal cancer; Ctrl, control.
    Cd8a Antibody, Anti Human, Reafinity, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd8a/CD8a+Antibody%2C+anti-human%2C+REAfinity/custom%40130-117-200%4042502392
    Average 94 stars, based on 1 article reviews
    cd8a antibody, anti-human, reafinity - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    anti cd8  (ABclonal Biotechnology)
    95
    ABclonal Biotechnology anti cd8
    Proangiogenic and immunosuppression phenotype of TANs in the CRLM microenvironment. A, Heatmap showing signature scores for angiogenesis, myeloid cell recruitment, neutrophil cytotoxicity, MDSC, and NET across each TAN and PMN subset. B, Comparison of angiogenesis, myeloid cell recruitment, MDSC, and NET signature scores among TAN and PMN subsets. C, Dot plot illustrating expression levels of major cytokines and chemokines in each TAN and PMN subset. D, Representative IHC images of CD31 staining in CRLM tissues. Scale bars, 50 µm. E, Correlation analysis between CD31 and TAN1 density using Spearman’s rank correlation ( n = 102). F, Representative images and quantification of tube formation in HUVECs when cocultured with conditioned medium from human LGALS3 − neutrophils or LGALS3 + neutrophils ( n = 6). G, UMAP plot showing six monocyte/macrophage subsets across colorectal cancer, adjacent liver tissues, CRLM, and PB samples. H, Shell-like plot depicting ligand–receptor interaction strength between TAN1_LGASL3 and neutrophil/monocyte/macrophage subset in CRLM. I, Selected ligand–receptor interactions between TAN1_LGASL3 and neutrophil/monocyte/macrophage subset in CRLM. J, Representative mIHC images of CD68, CCL3L1, CD66b, CCR1, and BHLHE40 in CRLM. Scale bars, 50 µm. K, Representative images of macrophage migration assays and effects of conditioned medium from human LGALS3 + neutrophils on migration of macrophages (induced from THP-1 cells) in the presence of CCR1 inhibitor (BX471) or anti-CCL3 antibody ( n = 6). L, Comparison of immunosuppressive macrophage signature scores between colorectal cancer and CRLM. M, Schematic of the CRLM mouse model. C57BL/6 mice received intrasplenic injections of mouse colorectal cancer cells (MC38). Mice were subsequently treated with IgG control (IgG; n = 6), anti-Ly6G antibody (anti-Ly6G; n = 6), or anti-Ly6G plus <t>anti-CD8a</t> antibodies (anti-Ly6G + anti-CD8a; n = 6). Livers were harvested on day 14. N, Representative images of liver metastases from IgG, anti-Ly6G, and anti-Ly6G + anti-CD8a groups. O, Comparison of liver weights among the three groups. P values were calculated by the Wilcoxon rank-sum test ( B and L ) and unpaired Student t test ( F , K , and O ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. CRC, colorectal cancer; Ctrl, control.
    Anti Cd8, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd8a/CD8A+Rabbit+pAb/10__1038_slash_s41420___026___03265___x-202-15-16
    Average 95 stars, based on 1 article reviews
    anti cd8 - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    Proangiogenic and immunosuppression phenotype of TANs in the CRLM microenvironment. A, Heatmap showing signature scores for angiogenesis, myeloid cell recruitment, neutrophil cytotoxicity, MDSC, and NET across each TAN and PMN subset. B, Comparison of angiogenesis, myeloid cell recruitment, MDSC, and NET signature scores among TAN and PMN subsets. C, Dot plot illustrating expression levels of major cytokines and chemokines in each TAN and PMN subset. D, Representative IHC images of CD31 staining in CRLM tissues. Scale bars, 50 µm. E, Correlation analysis between CD31 and TAN1 density using Spearman’s rank correlation ( n = 102). F, Representative images and quantification of tube formation in HUVECs when cocultured with conditioned medium from human LGALS3 − neutrophils or LGALS3 + neutrophils ( n = 6). G, UMAP plot showing six monocyte/macrophage subsets across colorectal cancer, adjacent liver tissues, CRLM, and PB samples. H, Shell-like plot depicting ligand–receptor interaction strength between TAN1_LGASL3 and neutrophil/monocyte/macrophage subset in CRLM. I, Selected ligand–receptor interactions between TAN1_LGASL3 and neutrophil/monocyte/macrophage subset in CRLM. J, Representative mIHC images of CD68, CCL3L1, CD66b, CCR1, and BHLHE40 in CRLM. Scale bars, 50 µm. K, Representative images of macrophage migration assays and effects of conditioned medium from human LGALS3 + neutrophils on migration of macrophages (induced from THP-1 cells) in the presence of CCR1 inhibitor (BX471) or anti-CCL3 antibody ( n = 6). L, Comparison of immunosuppressive macrophage signature scores between colorectal cancer and CRLM. M, Schematic of the CRLM mouse model. C57BL/6 mice received intrasplenic injections of mouse colorectal cancer cells (MC38). Mice were subsequently treated with IgG control (IgG; n = 6), anti-Ly6G antibody (anti-Ly6G; n = 6), or anti-Ly6G plus anti-CD8a antibodies (anti-Ly6G + anti-CD8a; n = 6). Livers were harvested on day 14. N, Representative images of liver metastases from IgG, anti-Ly6G, and anti-Ly6G + anti-CD8a groups. O, Comparison of liver weights among the three groups. P values were calculated by the Wilcoxon rank-sum test ( B and L ) and unpaired Student t test ( F , K , and O ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. CRC, colorectal cancer; Ctrl, control.

    Journal: Cancer Discovery

    Article Title: Senescent-Like Neutrophils Shape Angiogenic Immunosuppressive Niches in Colorectal Cancer Liver Metastasis

    doi: 10.1158/2159-8290.CD-25-0820

    Figure Lengend Snippet: Proangiogenic and immunosuppression phenotype of TANs in the CRLM microenvironment. A, Heatmap showing signature scores for angiogenesis, myeloid cell recruitment, neutrophil cytotoxicity, MDSC, and NET across each TAN and PMN subset. B, Comparison of angiogenesis, myeloid cell recruitment, MDSC, and NET signature scores among TAN and PMN subsets. C, Dot plot illustrating expression levels of major cytokines and chemokines in each TAN and PMN subset. D, Representative IHC images of CD31 staining in CRLM tissues. Scale bars, 50 µm. E, Correlation analysis between CD31 and TAN1 density using Spearman’s rank correlation ( n = 102). F, Representative images and quantification of tube formation in HUVECs when cocultured with conditioned medium from human LGALS3 − neutrophils or LGALS3 + neutrophils ( n = 6). G, UMAP plot showing six monocyte/macrophage subsets across colorectal cancer, adjacent liver tissues, CRLM, and PB samples. H, Shell-like plot depicting ligand–receptor interaction strength between TAN1_LGASL3 and neutrophil/monocyte/macrophage subset in CRLM. I, Selected ligand–receptor interactions between TAN1_LGASL3 and neutrophil/monocyte/macrophage subset in CRLM. J, Representative mIHC images of CD68, CCL3L1, CD66b, CCR1, and BHLHE40 in CRLM. Scale bars, 50 µm. K, Representative images of macrophage migration assays and effects of conditioned medium from human LGALS3 + neutrophils on migration of macrophages (induced from THP-1 cells) in the presence of CCR1 inhibitor (BX471) or anti-CCL3 antibody ( n = 6). L, Comparison of immunosuppressive macrophage signature scores between colorectal cancer and CRLM. M, Schematic of the CRLM mouse model. C57BL/6 mice received intrasplenic injections of mouse colorectal cancer cells (MC38). Mice were subsequently treated with IgG control (IgG; n = 6), anti-Ly6G antibody (anti-Ly6G; n = 6), or anti-Ly6G plus anti-CD8a antibodies (anti-Ly6G + anti-CD8a; n = 6). Livers were harvested on day 14. N, Representative images of liver metastases from IgG, anti-Ly6G, and anti-Ly6G + anti-CD8a groups. O, Comparison of liver weights among the three groups. P values were calculated by the Wilcoxon rank-sum test ( B and L ) and unpaired Student t test ( F , K , and O ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. CRC, colorectal cancer; Ctrl, control.

    Article Snippet: For CD8 + T-cell depletion, 200 μg anti-mouse CD8a (Bio X Cell, BE0061, RRID: AB_1125541) was injected intraperitoneally twice a week.

    Techniques: Comparison, Expressing, Staining, Analysis, Migration, Control